Syndax Pharmaceuticals, Inc. (SNDX)

NMS – Цена в реальном времени. Валюта: USD

20.42

+0.13 (0.64%)

Рынок открыт: Aug 12, 2026, 1:13 PM EDT

20.29

0.00 (0.00%)

Предыдущая сессия: Aug 11, 2026, 7:34 PM EDT

05.08.2026

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript

05.08.2026

Syndax Pharmaceuticals Q2 Earnings Call Highlights

Syndax Pharmaceuticals NASDAQ: SNDX reported second-quarter 2026 total revenue of $72.8 million, up 92% from the prior-year period, as sales of its leukemia treatment Revuforj and chronic graft-versus-host disease therapy Niktimvo continued to grow.

04.08.2026

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates

Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.83 per share a year ago.

04.08.2026

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

– Total revenue of $73 million in 2Q26, a 92% year-over-year increase – – Revuforj ® (revumenib) net revenue of $54.7 million in 2Q26, a 91% year-over-year increase – – Niktimvo™ (axatilimab-csfr) net revenue of $60.3 million in 2Q26, a 67% year-over-year increase, resulting in Syndax collaboration revenue of $18.1 million – – Expanded pipeline with a novel, mutant-selective, allosteric EGFR inhibitor for NSCLC and an internally developed next-generation menin inhibitor for myelofibrosis – – Topline data expected in 4Q26 from Phase 2 trials of axatilimab in IPF and frontline cGVHD – – Company to host a conference call today at 4:30 p.m. ET – NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today reported its financial results for the second quarter ended June 30, 2026, and provided a business update.

Видео

No Data

There is no data to display

Пресс-релизы

04.08.2026

Syndax Pharmaceuticals, Inc. (SNDX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Syndax Pharmaceuticals, Inc. (SNDX)

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript

Syndax Pharmaceuticals Q2 Earnings Call Highlights

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

Видео

No Data

Пресс-релизы

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript

Syndax Pharmaceuticals Q2 Earnings Call Highlights

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

Видео

No Data

Пресс-релизы

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

Search stocks

Syndax Pharmaceuticals, Inc. (SNDX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Syndax Pharmaceuticals, Inc. (SNDX)

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript

Syndax Pharmaceuticals Q2 Earnings Call Highlights

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

Видео

No Data

Пресс-релизы

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript

Syndax Pharmaceuticals Q2 Earnings Call Highlights

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

Видео

No Data

Пресс-релизы

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update